[HTML][HTML] O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents
T Walter, B Van Brakel, C Vercherat, V Hervieu… - British journal of …, 2015 - nature.com
Background: O 6-Methylguanine-DNA methyltransferase (MGMT) loss of expression has
been suggested to be predictive of response to temozolomide in neuroendocrine tumours …
been suggested to be predictive of response to temozolomide in neuroendocrine tumours …
Temozolomide: a milestone in neuro-oncology and beyond?
N Mutter, R Stupp - Expert review of anticancer therapy, 2006 - Taylor & Francis
Temozolomide (Temodal®, Temodar), an imidazol derivative, is a second-generation
alkylating agent. The orally available prodrug with the capacity of crossing the blood–brain …
alkylating agent. The orally available prodrug with the capacity of crossing the blood–brain …
[HTML][HTML] Temozolomide resistance in glioblastoma cell lines: implication of MGMT, MMR, P-glycoprotein and CD133 expression
Background The use of temozolomide (TMZ) has improved the prognosis for glioblastoma
multiforme patients. However, TMZ resistance may be one of the main reasons why …
multiforme patients. However, TMZ resistance may be one of the main reasons why …
Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles
GMV Barbagallo, S Paratore, R Caltabiano… - Neurosurgical …, 2014 - thejns.org
Object The objective of this study was to report the authors' experience with the long-term
administration of temozolomide (TMZ;> 6 cycles, up to 101) in patients with newly diagnosed …
administration of temozolomide (TMZ;> 6 cycles, up to 101) in patients with newly diagnosed …
Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in …
C Dai, B Zhang, X Liu, S Ma, Y Yang, Y Yao… - …, 2013 - academic.oup.com
Invasive pituitary adenomas (PAs) are often refractory to standard therapy and salvage
treatment with temozolomide (TMZ). Hyperactivation of the phosphoinositide 3-kinase …
treatment with temozolomide (TMZ). Hyperactivation of the phosphoinositide 3-kinase …
Mechanisms of disease: temozolomide and glioblastoma—look to the future
MM Mrugala, MC Chamberlain - Nature clinical practice Oncology, 2008 - nature.com
Glioblastoma is both the most common and most aggressive primary brain tumor. Until
recently, the standard of care involved maximal safe surgical resection followed by radiation …
recently, the standard of care involved maximal safe surgical resection followed by radiation …
MGMT promoter methylation in plasma of glioma patients receiving temozolomide
V Fiano, M Trevisan, E Trevisan, R Senetta… - Journal of neuro …, 2014 - Springer
Promoter methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene plays
a role in cellular response to alkylating agents. In the present study aimed to:(i) evaluate the …
a role in cellular response to alkylating agents. In the present study aimed to:(i) evaluate the …
New (alternative) temozolomide regimens for the treatment of glioma
One barrier to successful treatment of malignant glioma is resistance to alkylating agents
such as temozolomide. The cytotoxic activity of temozolomide and other alkylating agents is …
such as temozolomide. The cytotoxic activity of temozolomide and other alkylating agents is …
[HTML][HTML] Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
KA Van Nifterik, J Van Den Berg… - British journal of …, 2010 - nature.com
Background: The DNA repair protein O 6-methylguanine-DNA methyltransferase (MGMT)
can cause resistance to the alkylating drug temozolomide (TMZ). The purpose of this study …
can cause resistance to the alkylating drug temozolomide (TMZ). The purpose of this study …